🇺🇸 FDA
Patent

US 8791074

Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors

granted A61KA61K38/00A61K47/665

Quick answer

US patent 8791074 (Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61K47/665, A61P, A61P35/00